

IPR v. Ex Parte Reexam Strategy Considerations

A photograph of a modern building with a curved glass facade, showing multiple floors and windows, set against a light blue sky.

1 MIN READ

February 7, 2024, 7:16 AM

Looking forward to presenting at the AIPLA IP Practice in Japan Mid-Winter Program in Houston, TX next week!

I will be discussing the strategic considerations for *Inter Partes* Review (IPR) versus *Ex Parte* Reexamination, including:

- The procedural differences between IPR and *Ex Parte* Reexamination and associated statistics
- The circumstances when one may be preferable over the other
- The effects of timing and estoppel in parallel litigations

My colleague, [Jason Murata](#), another partner in Axinn's Intellectual Property group, will be covering, "Recent Developments in the Generic Pharma Industry in the U.S."



Related Services

Intellectual Property

To subscribe to our publications, [click here](#).

News & Insights

- GCR Live: Law Leaders Europe 2025
SPEAKING ENGAGEMENT ANTITRUST
- AHLA Annual Meeting 2025
SPEAKING ENGAGEMENT ANTITRUST
- SABA North America Annual Conference 2025
SPEAKING ENGAGEMENT ANTITRUST
- Navigating Compliance: How the 2025 Hart-Scott-Rodino Updates Are Impacting

Businesses

WEBINAR ANTITRUST

- NJSBA Annual Meeting and Convention 2025
SPEAKING ENGAGEMENT INTELLECTUAL PROPERTY
- Cost-Effective and Efficient IP Litigation Strategies – Making Paragraph IV Litigation Work for You
WEBINAR INTELLECTUAL PROPERTY
- Hartford HealthCare Black and Red Gala 2025
SPONSORSHIP ANTITRUST
- Informa CompLaw Antitrust West Coast Conference 2025
SPEAKING ENGAGEMENT ANTITRUST
- AHLA Health Care Transactions Program 2025
SPONSORSHIP ANTITRUST
- Five Healthcare Antitrust Topics to Watch at the Upcoming Health Care Transactions Conference in Nashville
AXINN VIEWPOINTS ANTITRUST